EP Patent

EP0041795A2 — Injectable composition of rapamycin

Assigned to Wyeth Canada Inc · Expires 1981-12-16 · 44y expired

What this patent protects

Described is an injectable composition comprising rapamycin and a nonionic surfactant selected from polyoxyethylated fatty acids, polyoxyethylated fatty alcohols or polyoxyethylated glycerine hydroxy fatty acid esters and a method of preparing said compositions. The composition p…

USPTO Abstract

Described is an injectable composition comprising rapamycin and a nonionic surfactant selected from polyoxyethylated fatty acids, polyoxyethylated fatty alcohols or polyoxyethylated glycerine hydroxy fatty acid esters and a method of preparing said compositions. The composition provides enhanced blood levels of rapamycin in a mammal following injected administration thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP0041795A2
Jurisdiction
EP
Classification
—
Expires
1981-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth Canada Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.